There is good agreement concerning average requirements and reference intakes for vitamin B6 but less agreement over safe upper levels from supplements. High-dose supplements cause sensory nerve damage. Supplements of vitamin B6 have been advocated for treatment of the premenstrual syndrome, with little evidence of efficacy. There are plausible mechanisms for an antidepressant action and protection against steroid hormone—dependent cancers but no evidence from clinical trials. Pyridoxamine reduces the glycation of proteins and so could be beneficial in preventing the adverse effects of poor glycemic control in diabetes. There are plausible mechanisms for an antihypertensive action but only suggestive evidence from small intervention trials. There is no evidence that supplements of vitamin B6 have any beneficial effect in hyperhomocysteinemia. There is neither a plausible mechanism nor any evidence from controlled trials for any effect of supplements of vitamin B6 in preventing a decline in cognitive function with aging, amelioration of dementia or autism, or improvement of the carpal tunnel syndrome.
Institute of Medicine.Dietary Reference Values for Thiamin, Riboflavin, Niacin, Vitamin B6, Folate, Vitamin B12, Pantothenic Acid, Biotin and Choline. Washington, DC: National Academies Press; 1998.
3.
Department of Health.Dietary Reference Values for Food Energy and Nutrients for the United Kingdom. London, UK: Her Majesty’s Stationery Office; 1991.
4.
Scientific Committee for Food.Nutrient and Energy Intakes for the European Community. Luxemburg: Commission of the European Communities; 1993 .
5.
Bates CJ, Pentieva KD, Prentice A.An appraisal of vitamin B6 status indices and associated confounders, in young people aged 4-18 years and in people aged 65 years and over, in two national British surveys. Public Health Nutr. 1999;2:529-535.
6.
Bender DALack of concordance between two indices of vitamin B6 nutritional status. Proc Nutr Soc. 1993;52:315a.
7.
Bender DANutritional Biochemistry of the Vitamins. 2nd ed. New York, NY: Cambridge University Press; 2003.
8.
Palm D., Klein HW, Schinzel R., et al. The role of pyridoxal 5’-phosphate in glycogen phosphorylase catalysis. Biochemistry. 1990;29:1099-1107.
9.
Bender DAOestrogens and vitamin B6: actions and interactions. World Rev Nutr Diet. 1987;51:140-188.
10.
Frimpter GW , Andelman RJ, George WFVitamin B6-dependency syndromes: new horizons in nutrition. Am J Clin Nutr. 1969;22:794-805.
11.
Mudd SHPyridoxine-responsive genetic disease. Fed Proc. 1971;30:970-976.
12.
Clayton PTB6-responsive disorders: a model of vitamin dependency. J Inherit Metab Dis. 2006;29:317-326.
13.
Lheureux P. , Penaloza A., Gris M.Pyridoxine in clinical toxicology: a review . Eur J Emerg Med. 2005 ;12:78-85.
14.
Phillips WE , Mills JH, Charbonneau SM, et al. Subacute toxicity of pyridoxine hydrochloride in the beagle dog. Toxicol Appl Pharmacol. 1978;44:323-333.
15.
Krinke G., Schaumburg HH, Spencer PS, et al. Pyridoxine megavitaminosis produces degeneration of peripheral sensory neurons (sensory neuropathy) in the dog. Neurotoxicology . 1980;2:13-24.
16.
Schaeppi U. , Krinke G.Pyridoxine neuropathy: correlation of functional tests and neuropathology in beagle dogs treated with large doses of vitamin B6. Agents Actions. 1982;12:575-582.
17.
Schaumburg H., Kaplan J., Windebank A., et al. Sensory neuropathy from pyridoxine abuse: a new megavitamin syndrome. N Engl J Med. 1983;309:445-448.
18.
Berger AR, Schaumburg HH, Schroeder C., et al. Dose response, coasting, and differential fiber vulnerability in human toxic neuropathy: a prospective study of pyridoxine neurotoxicity . Neurology. 1992;42:1367-1370.
19.
McLachlan RS , Brown WFPyridoxine dependent epilepsy with iatrogenic sensory neuronopathy. Can J Neurol Sci. 1995 ;22:50-51.
20.
Mpofu C., Alani SM, Whitehouse C., et al. No sensory neuropathy during pyridoxine treatment in homocystinuria . Arch Dis Child. 1991;66:1081-1082.
21.
Brush MG, Bennett T., Hansen K.Pyridoxine in the treatment of premenstrual syndrome: a retrospective survey in 630 patients. Br J Clin Pract. 1988 ;42:448-452.
22.
Dalton K., Dalton MJCharacteristics of pyridoxine overdose neuropathy syndrome. Acta Neurol Scand. 1987;76:8-11.
23.
Scientific Committee on Food.Opinion of the Scientific Committee on Food on the Tolerable Upper Intake Level of Vitamin B6 . http://ec.europa.eu/food/fs/sc/scf/out80c_en.pdf . Accessed August 15, 2010.
24.
Expert Group on Vitamins and Minerals.Safe upper levels for vitamins and minerals. http://www.foodstandards.gov.uk/science/ouradvisors/vitandmin . Accessed August 15, 2010.
25.
Rose DPExcretion of xanthurenic acid in the urine of women taking progesterone-oestrogen preparations. Nature. 1966;210: 196-197.
26.
Rose DPThe influence of oestrogens on tryptophan metabolism in man. Clin Sci. 1966;31:265-272.
27.
Bender DA, Wynick D.Inhibition of kynureninase (L-kynurenine hydrolase, EC 3.7.1.3) by oestrone sulphate: an alternative explanation for abnormal results of tryptophan load tests in women receiving oestrogenic steroids. Br J Nutr . 1981;45:269-275.
28.
Meister A.On the transamination of enzymes. Ann N Y Acad Sci . 1990;585:13-31.
29.
Allgood VE, Powell-Oliver FE, Cidlowski JAThe influence of vitamin B6 on the structure and function of the glucocorticoid receptor. Ann N Y Acad Sci. 1990;585:452-465.
30.
Tully DB, Allgood VE, Cidlowski JAModulation of steroid receptor-mediated gene expression by vitamin B6. FASEB J. 1994;8:343-349.
31.
Allgood VE, Cidlowski JAVitamin B6 modulates transcriptional activation by multiple members of the steroid hormone receptor superfamily. J Biol Chem. 1992;267:3819-3824.
32.
Ritchie CD, Singkamani R.Plasma pyridoxal 5’-phosphate in women with the premenstrual syndrome . Hum Nutr Clin Nutr. 1986;40:75-80.
33.
van den Berg H., Louwerse ES, Bruinse HW, et al. Vitamin B6 status of women suffering from premenstrual syndrome. Hum Nutr Clin Nutr. 1986;40:441-450.
34.
Mira M., Stewart PM, Abraham SFVitamin and trace element status in premenstrual syndrome. Am J Clin Nutr. 1988;47:636-641.
35.
Kleijnen J. , Ter Riet G., Knipschild P.Vitamin B6 in the treatment of the premenstrual syndrome: a review. Br J Obstet Gynaecol . 1990;97:847-852.
36.
Hagen I., Nesheim BI, Tuntland T.No effect of vitamin B-6 against premenstrual tension: a controlled clinical study. Acta Obstet Gynecol Scand. 1985;64:667-670.
37.
Whelan AM, Jurgens TM, Naylor H.Herbs, vitamins and minerals in the treatment of premenstrual syndrome: a systematic review. Can J Clin Pharmacol. 2009 ;16:e407-e429.
38.
Jewell D., Young G.Interventions for nausea and vomiting in early pregnancy. Cochrane Database Syst Rev. 2003(4):CD000145.
39.
Schuster K. , Bailey LB, Dimperio D., et al. Morning sickness and vitamin B6 status of pregnant women. Hum Nutr Clin Nutr . 1985 ; 39:75-79.
40.
Brent RLBendectin: review of the medical literature of a comprehensively studied human nonteratogen and the most prevalent tortogen-litigen. Reprod Toxicol. 1995;9:337-349.
41.
Thaver D., Saeed MA, Bhutta ZAPyridoxine (vitamin B6) supplementation in pregnancy. Cochrane Database Syst Rev. 2006; (2):CD000179.
42.
Kutcher JS, Engle A., Firth J., et al. Bendectin and birth defects. II: Ecological analyses. Birth Defects Res A Clin Mol Teratol. 2003; 67:88-97.
43.
Bender DABiochemistry of tryptophan in health and disease. Mol Aspects Med. 1983;6:101-197.
44.
Dakshinamurti K., LeBlancq WD, Herchl R., et al. Nonparallel changes in brain monoamines of pyridoxine-deficient growing rats. Exp Brain Res. 1976;26:355-366.
45.
Perry TL, Yong VW, Kish SJ, et al. Neurochemical abnormalities in brains of renal failure patients treated by repeated hemodialysis. J Neurochem. 1985;45:1043-1048.
46.
Bender DA, Totoe L.High doses of vitamin B6 in the rat are associated with inhibition of hepatic tryptophan metabolism and increased uptake of tryptophan into the brain. J Neurochem. 1984;43:733-736.
47.
Belongia EA , Mayeno AN, Osterholm MTThe eosinophilia-myalgia syndrome and tryptophan . Annu Rev Nutr. 1992;12: 235-256.
48.
Varga J., Uitto J., Jimenez SAThe cause and pathogenesis of the eosinophilia-myalgia syndrome. Ann Intern Med. 1992;116: 140-147.
49.
Wynn V., Doar JWSome effects of oral contraceptives on carbohydrate metabolism. Lancet. 1966;(ii):715-719.
50.
Bennink HJ, Schreurs WHImprovement of oral glucose tolerance in gestational diabetes by pyridoxine . Br Med J. 1975;3: 13-15.
51.
Adams PW, Wynn V., Folkard J., et al. Influence of oral contraceptives, pyridoxine (vitamin B6) and tryptophan on carbohydrate metabolism. Lancet. 1976;(i):759-764.
52.
Spellacy WN , Buhi WC, Birk SAVitamin B6 treatment of gestational diabetes mellitus: studies of blood glucose and plasma insulin . Am J Obstet Gynecol. 1977;127:599-602.
53.
Rose DP, Leklem JE, Brown RR, et al. Effect of oral contraceptives and vitamin B6 deficiency on carbohydrate metabolism. Am J Clin Nutr. 1975;28:872-878.
54.
Bender DA, Totoe L.Inhibition of tryptophan metabolism by oestrogens in the rat: a factor in the aetiology of pellagra. Br J Nutr. 1984 ;51:219-224.
55.
van de Kamp JL, Smolen A.Response of kynurenine pathway enzymes to pregnancy and dietary level of vitamin B-6. Pharmacol Biochem Behav. 1995;51:753-758.
56.
Kotake Y., Ueda T., Mori T., et al. The physiological significance of the xanthurenic acid-insulin complex. J Biochem (Tokyo). 1975;77:685-687.
57.
Noto Y., Okamoto H.Inhibition by kynurenine metabolites of proinsulin synthesis in isolated pancreatic islets. Acta Diabetol Lat. 1978 ;15(5-6):273-282.
58.
Rogers KS, Evangelista SJ3-Hydroxykynurenine, 3-hydroxy-anthranilic acid, and o-aminophenol inhibit leucine-stimulated insulin release from rat pancreatic islets. Proc Soc Exp Biol Med. 1985;178:275-278.
59.
Solomon LR, Cohen K.Erythrocyte O2 transport and metabolism and effects of vitamin B6 therapy in type II diabetes mellitus. Diabetes. 1989 ;38:881-886.
60.
Ganea E., Harding JJLens proteins changes induced by sugars and pyridoxal phosphate. Ophthalmic Res. 1996;28(suppl 1): 65-68.
61.
Voziyan PA, Hudson BGPyridoxamine: the many virtues of a Maillard reaction inhibitor. Ann N Y Acad Sci. 2005;1043:807-816.
62.
Voziyan PA, Hudson BGPyridoxamine as a multifunctional pharmaceutical: targeting pathogenic glycation and oxidative damage. Cell Mol Life Sci. 2005 ;62:1671-1681.
63.
Chang KC, Liang JT, Tsai PS, et al. Prevention of arterial stiffening by pyridoxamine in diabetes is associated with inhibition of the pathogenic glycation on aortic collagen . Br J Pharmacol. 2009;157:1419-1426.
64.
Hagiwara S. , Gohda T., Tanimoto M., et al. Effects of pyridoxamine (K-163) on glucose intolerance and obesity in high-fat diet C57BL/6J mice. Metabolism. 2009;58:934-945.
65.
Murakoshi M. , Tanimoto M., Gohda T., et al. Pleiotropic effect of pyridoxamine on diabetic complications via CD36 expression in KK-Ay/Ta mice. Diabetes Res Clin Pract. 2009;83:183-189.
66.
Tanimoto M. , Gohda T., Kaneko S., et al. Effect of pyridoxamine (K-163), an inhibitor of advanced glycation end products, on type 2 diabetic nephropathy in KK-A(y)/Ta mice. Metabolism. 2007; 56:160-167.
67.
Padival S., Nagaraj RHPyridoxamine inhibits Maillard reactions in diabetic rat lenses. Ophthalmic Res. 2006;38:294-302.
68.
Zheng F., Zeng YJ, Plati AR, et al. Combined AGE inhibition and ACEi decreases the progression of established diabetic nephropathy in B6 db/db mice. Kidney Int. 2006;70:507-514.
69.
Williams ME , Bolton WK, Khalifah RG, et al. Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathy . Am J Nephrol. 2007;27: 605-614.
70.
Verhoef P., Stamler MJProspective studies of homocysteine and cardiovascular disease. Nutr Rev. 1995;53:283-288.
71.
Boers GHJ.Hyperhomocysteinaemia as a risk factor for arterial and venous disease: a review of evidence and relevance. Thromb Haemost. 1997;78:520-522.
72.
D’Angelo A., Selhub J.Homocysteine and thrombotic disease . Blood. 1997;90:1-11.
73.
Linkswiler HMMethionine metabolism as affected by vitamin B-6 deficiency. In: Leklem JE, Reynolds RD, eds. Methods in Vitamin B-6 Nutrition: Analysis and Status Assessment. New York, NY: Plenum Press;1981:373-382.
74.
Selhub J., Jacques PF, Wilson PW, et al. Vitamin status and intake as primary determinants of homocysteinemia in an elderly population. JAMA. 1993;270:2693-2698.
75.
Clarke R., Armitage J.Vitamin supplements and cardiovascular risk: review of the randomized trials of homocysteine-lowering vitamin supplements. Semin Thromb Hemost. 2000;26:341-348.
76.
Marti-Carvajal AJ, Sola I., Lathyris D., et al. Homocysteine lowering interventions for preventing cardiovascular events. Cochrane Database Syst Rev. 2009;(4):CD006612.
77.
Sanchez-Moreno C., Jimenez-Escrig A., Martin A.Stroke: roles of B vitamins, homocysteine and antioxidants. Nutr Res Rev. 2009; 22:49-67.
78.
McNulty H., Pentieva K., Hoey L., et al. Homocysteine, B-vitamins and CVD. Proc Nutr Soc. 2008;67:232-237.
79.
Spence JDHomocysteine-lowering therapy: a role in stroke prevention? Lancet Neurol. 2007;6:830-838.
80.
Perna AF, Ingrosso D., Violetti E., et al. Hyperhomocysteinemia in uremia: a red flag in a disrupted circuit . Semin Dial. 2009;22: 351-356.
81.
Friedman ANPharmacologic B-vitamin therapy for hyperhomocysteinemia in dialysis patients: has the time come? Nutr Clin Care. 2002;5:20-24.
82.
Dakshinamurti K., Lal KJVitamins and hypertension. World Rev Nutr Diet. 1992;69:40-73.
Dakshinamurti K., Dakshinamurti S.Blood pressure regulation and micronutrients . Nutr Res Rev. 2001;14:3-44.
85.
Dakshinamurti K., Lal KJ, Ganguly PKHypertension, calcium channel and pyridoxine (vitamin B6). Mol Cell Biochem. 1998;188:137-148.
86.
Vasdev S., Wadhawan S., Ford CA, et al. Dietary vitamin B6 supplementation prevents ethanol-induced hypertension in rats. Nutr Metab Cardiovasc Dis. 1999;9:55-63.
87.
Vasdev S., Ford CA, Parai S., et al. Dietary vitamin B6 supplementation attenuates hypertension in spontaneously hypertensive rats. Mol Cell Biochem. 1999;200:155-162.
88.
Lal KJ, Dakshinamurti K., Thliveris J.The effect of vitamin B6 on the systolic blood pressure of rats in various animal models of hypertension. J Hypertens. 1996;14:355-363.
89.
Fregly MJ, Cade JREffect of pyridoxine and tryptophan, alone and combined, on the development of deoxycorticosterone acetate-induced hypertension in rats. Pharmacology. 1995;50:298-306.
90.
Lin PT, Cheng CH, Wei JC, et al. Low plasma pyridoxal 5’phosphate concentration and MTHFR 677C->T genotypes are associated with increased risk of hypertension . Int J Vitam Nutr Res. 2008;78:33-40.
91.
Aybak M., Sermet A., Ayyildiz MO, et al. Effect of oral pyridoxine hydrochloride supplementation on arterial blood pressure in patients with essential hypertension. Arzneimittelforschung . 1995;45:1271-1273.
92.
Chan P., Huang TY, Chen YJ, et al. Randomized, double-blind, placebo-controlled study of the safety and efficacy of vitamin B complex in the treatment of nocturnal leg cramps in elderly patients with hypertension. J Clin Pharmacol. 1998;38:1151-1154.
93.
Brophy MH, Siiteri PKPyridoxal phosphate and hypertensive disorders of pregnancy. Am J Obstet Gynecol. 1975;121:1075-1079.
94.
Riggs KM, Spiro A. III, Tucker K., et al. Relations of vitamin B-12, vitamin B-6, folate, and homocysteine to cognitive performance in the Normative Aging Study. Am J Clin Nutr. 1996;63:306-314.
95.
Spinneker A. , Sola R., Lemmen V., et al. Vitamin B6 status, deficiency and its consequences: an overview. Nutr Hosp. 2007;22:7-24.
96.
Deijen JB, van der Beek EJ, Orlebeke JF, et al. Vitamin B-6 supplementation in elderly men: effects on mood, memory, performance and mental effort. Psychopharmacology (Berl). 1992;109:489-496.
97.
Molimard R. , Marillaud A., Paille A., et al. Impairment of memorization by high doses of pyridoxine in man. Biomedicine . 1980 ;32:88-92.
98.
Balk E., Chung M., Raman G., et al. B vitamins and berries and age-related neurodegenerative disorders . Evid Rep Technol Assess (Full Rep). 2006;(134):1-161.
99.
Balk EM, Raman G., Tatsioni A., et al. Vitamin B6, B12, and folic acid supplementation and cognitive function: a systematic review of randomized trials. Arch Intern Med. 2007;167:21-30.
100.
Malouf R., Grimley Evans J.The effect of vitamin B6 on cognition. Cochrane Database Syst Rev. 2003;(4):CD004393.
101.
Morris MC, Schneider JA, Tangney CCThoughts on B-vitamins and dementia. J Alzheimers Dis. 2006;9:429-433.
102.
Nye C. , Brice A.Combined vitamin B6-magnesium treatment in autism spectrum disorder. Cochrane Database Syst Rev. 2005; (4):CD003497.
103.
Rossignol DANovel and emerging treatments for autism spectrum disorders: a systematic review. Ann Clin Psychiatry. 2009; 21:213-236.
104.
Potera C., Rose DP, Brown RRVitamin B6 deficiency in cancer patients. Am J Clin Nutr. 1977;30:1677-1679.
105.
Bell E.The excretion of a vitamin B6 metabolite and the probability of recurrence of early breast cancer. Eur J Cancer. 1980 ;16:297-298.
106.
Key TJ, Silcocks PB, Davey GK, et al. A case-control study of diet and prostate cancer. Br J Cancer. 1997;76:678-687.
107.
Larsson SC, Orsini N., Wolk A.Vitamin B6 and risk of colorectal cancer: a meta-analysis of prospective studies . JAMA. 2010;303: 1077-1083.
108.
Komatsu SI, Watanabe H., Oka T., et al. Vitamin B-6-supplemented diets compared with a low vitamin B-6 diet suppress azoxymethane-induced colon tumorigenesis in mice by reducing cell proliferation. J Nutr. 2001;131:2204-2207.
109.
Komatsu S. , Yanaka N., Matsubara K., et al. Antitumor effect of vitamin B6 and its mechanisms. Biochim Biophys Acta. 2003 ; 1647:127-130.
110.
Matsubara K., Komatsu S., Oka T., et al. Vitamin B6-mediated suppression of colon tumorigenesis, cell proliferation, and angiogenesis (review) . J Nutr Biochem. 2003;14:246-250.
111.
Ebbing M., Bonaa KH, Nygard O., et al. Cancer incidence and mortality after treatment with folic acid and vitamin B12. JAMA. 2009;302:2119-2126.
112.
Ellis JM, Kishi T., Azuma J., et al. Vitamin B6 deficiency in patients with a clinical syndrome including the carpal tunnel defect: biochemical and clinical response to therapy with pyridoxine. Res Commun Chem Pathol Pharmacol. 1976;13:743-757.
113.
Ellis JM, Azuma J., Watanabe T., et al. Survey and new data on treatment with pyridoxine of patients having a clinical syndrome including the carpal tunnel and other defects. Res Commun Chem Pathol Pharmacol. 1977;17:165-177.
114.
Folkers K. , Ellis J., Watanabe T., et al. Biochemical evidence for a deficiency of vitamin B6 in the carpal tunnel syndrome based on a crossover clinical study. Proc Natl Acad Sci U S A. 1978;75: 3410-3412.
115.
Ellis J., Folkers K., Watanabe T., et al. Clinical results of a crossover treatment with pyridoxine and placebo of the carpal tunnel syndrome. Am J Clin Nutr. 1979;32:2040-2046.
116.
Ellis J., Folkers K., Levy M., et al. Therapy with vitamin B6 with and without surgery for treatment of patients having the idiopathic carpal tunnel syndrome. Res Commun Chem Pathol Pharmacol. 1981;33:331-344.
117.
Ellis JMTreatment of carpal tunnel syndrome with vitamin B6. South Med J. 1987;80:882-884.
118.
Aufiero E. , Stitik TP, Foye PM, et al. Pyridoxine hydrochloride treatment of carpal tunnel syndrome: a review. Nutr Rev. 2004;62:96-104.
119.
O’Connor D., Marshall S., Massy-Westropp N.Non-surgical treatment (other than steroid injection) for carpal tunnel syndrome. Cochrane Database Syst Rev. 2003;(1): CD003219.
120.
Piazzini DB , Aprile I., Ferrara PE, et al. A systematic review of conservative treatment of carpal tunnel syndrome. Clin Rehabil. 2007;21:299-314.
